These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 20542058)

  • 1. Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents.
    Visentin M; Biason P; Toffoli G
    Pharmacol Ther; 2010 Oct; 128(1):82-90. PubMed ID: 20542058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM; Allen GW; Bonner JA
    J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
    Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.
    Thomas SM; Grandis JR
    Cancer Treat Rev; 2004 May; 30(3):255-68. PubMed ID: 15059649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
    Mould DR; Sweeney KR
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):84-96. PubMed ID: 17265746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug interactions and clinical relevance: it all began with cheese].
    Carrillo Norte JA
    Rev Enferm; 2012 Apr; 35(4):8-18. PubMed ID: 22745995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological interactions of monoclonal antibodies.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2018 Aug; 151(4):148-155. PubMed ID: 29269128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy for controlling potential interactions between natural health products and chemotherapy: a review in pediatric oncology.
    Seely D; Stempak D; Baruchel S
    J Pediatr Hematol Oncol; 2007 Jan; 29(1):32-47. PubMed ID: 17230065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Absorption, distribution, metabolism, excretion and toxicity of biologics and its application in pharmacokinetic modeling].
    Zhang CF; Xie HT; Pan GY
    Yao Xue Xue Bao; 2016 Aug; 51(8):1202-8. PubMed ID: 29897713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
    Zheng S; McIntosh T; Wang W
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced alterations in Mg2+ homoeostasis.
    Lameris AL; Monnens LA; Bindels RJ; Hoenderop JG
    Clin Sci (Lond); 2012 Jul; 123(1):1-14. PubMed ID: 22409531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal Growth Factor and Epidermal Growth Factor Receptor: The Yin and Yang in the Treatment of Cutaneous Wounds and Cancer.
    Bodnar RJ
    Adv Wound Care (New Rochelle); 2013 Feb; 2(1):24-29. PubMed ID: 24527320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology considerations in biologics development.
    Zhao L; Ren TH; Wang DD
    Acta Pharmacol Sin; 2012 Nov; 33(11):1339-47. PubMed ID: 23001474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.